Lilly C M, Drazen J M, Shore S A
Department of Medicine, Beth Israel Hospital, Boston, Massachusetts.
Proc Soc Exp Biol Med. 1993 Sep;203(4):388-404. doi: 10.3181/00379727-203-43616.
SP and NKA are potent endogenous bronchoconstrictors, whereas VIP is a potent endogenous bronchodilator. There is abundant evidence that these neuropeptides are released in the lung in a variety of conditions and that they have the capacity to modulate the bronchoactivity of the same stimuli that release them. On many occasions, their bronchoactive effects are masked by their degradation at or near the site of their release. However, when the microenvironment is modified to decrease their cleavage, they can express enhanced physiologic effects. Although it appears that the human asthmatic lung may be an environment in which the effects of neuropeptides can be amplified, the role of neuropeptides in the pathogenesis of airway obstruction remains speculative.
速激肽（SP）和神经激肽A（NKA）是强效的内源性支气管收缩剂，而血管活性肠肽（VIP）是强效的内源性支气管扩张剂。有充分证据表明，这些神经肽在多种情况下会在肺中释放，并且它们有能力调节释放它们的相同刺激的支气管活性。在许多情况下，它们的支气管活性作用会因其在释放部位或附近被降解而被掩盖。然而，当微环境被改变以减少它们的裂解时，它们可以表现出增强的生理效应。虽然看起来人类哮喘肺可能是一个神经肽作用可以被放大的环境，但神经肽在气道阻塞发病机制中的作用仍具有推测性。
